2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Conditions
Glioblastoma
5
Lung Neoplasms
4
Head and Neck Neoplasms
4
Breast Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Glioma
3
Brain Neoplasms
3
Virus Diseases
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Neoplasms
2
Melanoma
2
Liver Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Pharyngeal Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Nose Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Interventions
Temozolomide
131
Radiotherapy
87
Bevacizumab
43
Radiation
31
Carmustine
29
Magnetic Resonance Spectroscopy
22
Irinotecan
22
Erlotinib Hydrochloride
22
Chemotherapy, Adjuvant
20
Surgical Procedures, Operative
15
O(6)-benzylguanine
15
Carboplatin
14
Radiotherapy, Intensity-Modulated
13
Radiotherapy, Conformal
13
sargramostim
12
Sirolimus
9
Imatinib Mesylate
9
Filgrastim
9
Drug Therapy
9
temsirolimus
8
Thalidomide
8
Sorafenib
8
Radiosurgery
8
pembrolizumab
7
motexafin gadolinium
7
aldesleukin
7
Vorinostat
7
Procarbazine
7
Gene Expression Profiling
7
Gefitinib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Gliosarcoma
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled